vaccines
(9)
The 176-Year-Old Startup That Sells Science by the Milligram
It began as a candy-flavored worm medicine in a Brooklyn brick house. Today Pfizer is racing to replace its Covid windfall with cancer drugs and weight-loss pills before the patents run out.
The 245-Year-Old Drugmaker Betting Its Next Act on Six Big Swings
Takeda began as a medicine shop in Osaka in 1781. Now a new CEO must turn a sprawling global portfolio, a $30 billion-plus revenue base and six late-stage programs into the company’s next generation of growth.
Moderna Designed Its COVID Vaccine in Two Days. The Hard Part Took Ten Years.
The Cambridge biotech turned messenger RNA from a lab curiosity into a platform for printing medicines from genetic code - vaccines, cancer shots, and rare-disease drugs that share one factory and swap out the instructions.
GSK
After spinning off toothpaste and painkillers, GSK placed a sharper bet on the immune system. Its next chapter is being written in vaccine vials, long-acting HIV medicine and a newly enlarged cancer pipeline.
Sanofi
The 53-year-old French drugmaker is narrowing its bets to immunology, vaccines and a faster pipeline. The wager is that better biology, selective dealmaking and factory-scale AI can turn scientific focus into repeatable growth.
Merck
KEYTRUDA made Merck an oncology powerhouse. Now the 135-year-old drugmaker is spending, partnering and inventing its way toward a future that cannot depend on one medicine.
Willog
Willog is a Seoul-based AIoT supply chain company that turns invisible logistics events into data. Its patented sensor devices track temperature, shock, humidity and location across warehouse, road, ocean and air, feeding an AI-powered Control Tower that gives shippers of pharmaceuticals, semiconductors, chemicals and food real-time visibility, diagnostics and risk prediction. Founded in 2021, Willog serves 200+ global enterprise customers and reached a Series B-2 round in under five years.
Dynavax Technologies
Dynavax Technologies is an Emeryville, California biopharmaceutical company built around CpG 1018, a proprietary vaccine adjuvant that sharpens the immune system's response. Its flagship product, HEPLISAV-B, is the first and only two-dose adult hepatitis B vaccine approved in the U.S. and Europe, and had grown to roughly 44% U.S. market share by the end of 2024. Beyond hepatitis B, Dynavax licenses CpG 1018 to other vaccine developers - most visibly as an ingredient in several COVID-19 vaccines - and has advanced its own pipeline in shingles, plague, pandemic influenza, and Lyme disease. In December 2025 Sanofi agreed to acquire Dynavax for about $2.2 billion; the deal closed in February 2026.
Biotechnology Innovation Organization
The Biotechnology Innovation Organization (BIO) is the world's largest trade association for the biotech industry, representing more than 1,000 companies, research institutions and state and regional bio centers across the United States and 30-plus countries. Founded in 1993 and headquartered in Washington, D.C., BIO lobbies on drug pricing, intellectual property, regulation and biosecurity, and runs the BIO International Convention - the industry's flagship annual dealmaking and networking event. Led since 2024 by President and CEO John F. Crowley, a rare-disease entrepreneur whose own children have Pompe disease, BIO's stated mission is to advance a 'bio revolution' that cures patients, protects the climate and nourishes humanity.